Pilot, research, and investor overview
SyncSOAP is a clinician-founded AI documentation platform beginning with dermatology, built around careful validation, faithfulness-focused SOAP note generation, and a staged path toward broader outpatient workflows.
Compliance posture
SyncSOAP is currently being validated in mock and non-PHI settings. Use with protected health information requires HIPAA-eligible infrastructure, executed business associate agreements, access controls, retention policies, and customer approval.
Current stage
Validation in mock and non-PHI settings, with staged progression before any PHI-enabled pilot.
Differentiation
Dermatology-first validation, cost-aware model routing, and faithfulness-first documentation design.
Intended collaborators
Physician collaborators, pilot sites, investors, research partners, and grant reviewers.
Current Validation Stage
The product is being evaluated before live PHI use
The near-term goal is careful workflow validation, model benchmarking, and measurement of note quality before any PHI-enabled pilot is considered.
Mock-patient study workflow
No live PHI in validation
Model comparison across latency, cost, and clinical faithfulness
Human-reviewed grading of completeness and hallucination risk
Pilot Participation
Who should reach out
We are interested in collaborators who want to help validate documentation workflows through a staged pilot structure.
Dermatology clinics
Physicians interested in workflow validation
Medical students and research collaborators
Academic partners
Pilot Stages
A staged path from mock validation to limited production use
The pilot design is intentionally progressive. Each stage is meant to validate workflow safety, documentation quality, and implementation readiness before the next one opens.
Stage 0: mock-patient validation
Stage 1: non-PHI workflow testing
Stage 2: limited PHI-enabled pilot only after BAAs and approvals
Research Metrics
What we plan to measure
Evaluation is centered on note quality, clinician burden, and operational feasibility rather than marketing-style output claims.
Time to signable note
Completeness
Unsupported additions and hallucinations
Editing burden
Model latency
Cost per note
Clinician usability
Investor View
Why SyncSOAP May Be Different
The strategy is to begin with a focused dermatology use case, build evidence around faithfulness-focused documentation, and develop the model governance and workflow controls needed for broader outpatient expansion.
Dermatology-first wedge
Faithfulness-first documentation
Cost-aware model routing
Model governance layer
Research-driven validation
Broader outpatient expansion path
Category Momentum
Why we believe the market is moving in this direction
Large funding rounds and market growth estimates do not prove product-market fit for SyncSOAP, but they do support the broader thesis that clinical documentation remains a major area of healthcare AI investment.
Abridge announced a $150 million funding round in February 2024 focused on clinical documentation AI.
Suki announced a $70 million funding round in October 2024 to expand its AI assistant and scribe capabilities.
One U.S. market estimate sized AI medical scribing at about $397 million in 2024 and projected growth toward roughly $3.0 billion by 2033.
Expansion Path
From Dermatology to Broader Outpatient Workflows
The current focus is dermatology workflow validation, with a planned path into broader outpatient documentation and then specialty-specific workflow layers as evidence and controls develop.
Phase 1: Dermatology workflows
Phase 2: General outpatient documentation
Phase 3: Specialty-specific workflows
What we're building
Documentation support, not autonomous care
SyncSOAP is designed to support reviewable draft documentation. It is not intended to replace physician judgment, provide autonomous diagnosis, or operate as unattended clinical decision-making software.
Built on HIPAA-eligible infrastructure
The architecture is being shaped to support future PHI-enabled deployment, while live PHI remains unavailable until the required agreements and controls are in place.
Contact
Start a conversation
If you are evaluating SyncSOAP for a pilot, investment conversation, partnership, or research collaboration, reach out directly.